ArticleSleep & breathing = Schlaf & Atmung2026
Glycemic trends following hypoglossal nerve stimulation in patients with obstructive sleep apnea and type 2 diabetes.
Article in Sleep & breathing = Schlaf & Atmung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo describe glycemic trends following hypoglossal nerve stimulation (HNS) therapy in patients with obstructive sleep apnea (OSA) and type 2 diabetes.
methodsA retrospective review was conducted of patients with type 2 diabetes who underwent HNS therapy at an academic institution. The study population consisted of 17 diabetic patients who received HNS therapy between Jan 2020 to Oct 2024. Data collected included patient demographics, as well as baseline and post-operative apnea-hypopnea index (AHI) values obtained via polysomnography to assess OSA severity. Diabetes-related parameters included hemoglobin A1c (HbA1c), insulin use, and diabetes medication use. Statistical analyses were performed using IBM SPSS Statistics version 31.0.1.0 with P < 0.05 considered statistically significant.
resultsThe cohort was 52.9% male with a mean age of 65.3 ± 6.4 years, body mass index of 30.4 ± 3.6 kg/m2, and baseline AHI of 32.4 ± 14.4 events/h. Post-implantation, mean HbA1c decreased from 6.60 to 6.26 (mean change -0.31, p = 0.24). Of the 6 patients who were insulin-dependent prior to HNS implantation, 3 (50%) were able to discontinue insulin use during follow-up. Pearson correlation analysis demonstrated an association between AHI improvement and HbA1c improvement (r = -0.69, p = 0.027). Greater reductions in medication burden were significantly associated with improvements in both AHI and HbA1c.
conclusionIn this retrospective cohort, HNS therapy was associated with trends toward lower HbA1c and reduced insulin dependence, although these findings did not reach statistical significance. These results underscore the need for further studies to better understand the role of HNS in improving glycemic control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.